Carcinoid Tumor: Advances in Treatment Options

Urwat T. Vusqa 1, Stuti Patel 2, Mamoon Ur Rashid 3, Deepika Sarvepalli 4, Abu H. Khan 5

1. Internal Medicine, Army Medical College, Rawalpindi, PAK 2. Internal Medicine, Gujarat Medical Education and Research Society Medical College, Vadodara, IND 3. Internal Medicine, AdventHealth, Orlando, USA 4. Internal Medicine, Guntur Medical College, Guntur, IND 5. Gastroenterology, AdventHealth, Orlando, USA

Corresponding author: Deepika Sarvepalli, sarvepalli.deepika@gmail.com

Abstract

Small bowel neoplasms are rare, accounting for only 3%-6% of all gastrointestinal neoplasms. Carcinoid tumors represent a large portion of these (20%-30%), making them the second most common small bowel malignancy after adenocarcinoma. Gastrointestinal carcinoids constitute 70% of all neuroendocrine tumors, and out of those, 42% originate in the small bowel. They are predominantly seen in older patients around the age of 65 years. From 1973 to 2004, there has been more than a fourfold increase in the incidence of carcinoid tumors. This can be probably due to increased diagnostic accuracy rather than an actual increase in the number of new cases. The workup of a suspicious case of gastrointestinal bleeding consists of esophagogastroduodenoscopy and/or colonoscopy, and other imaging tests including video capsule endoscopy and balloon-assisted endoscopy. Management of the tumors is dependent on the size and location of the lesion. Treatment options include surgery, endoscopic removal of tumors, and various immunotherapy and chemotherapeutic agents.

Introduction

Small bowel neoplasms are uncommon, accounting for only 3%-6% of all gastrointestinal (GI) neoplasms. Carcinoid tumors represent the second most common (20%-30%) small bowel malignancy after adenocarcinoma. GI carcinoids constitute 70% of all neuroendocrine tumors (NETs), and out of those, 42% originate in the small bowel [1,2]. They are predominantly seen in older patients around the age of 65 years [3]. The incidence of NETs is rare, constituting 0.5% of all newly diagnosed malignancies [4].

From 1973 to 2004, there has been more than a fourfold increase in the incidence of carcinoid tumors [5]. This can be probably due to increased diagnostic accuracy rather than an actual increase in the number of new cases [2]. We present a case of a carcinoid tumor that presented with GI bleed and anemia. The patient had normal findings on esophagogastroduodenoscopy and colonoscopy, and was provisionally diagnosed with malignancy on computerized tomography (CT) abdomen/pelvis with contrast.

Case Presentation

A 52-year-old otherwise healthy man presented to his primary care physician with complaints of bleeding per rectum for the past six days. He described the stools as dark in color and pasty in consistency. He also complained of colicky right lower quadrant abdominal pain. Physical
examination was unremarkable except for mild generalized abdominal pain. He was found to have a hemoglobin of 9 mg/dl, and was referred to the emergency room for evaluation. Further lab studies revealed iron deficiency anemia, and fecal occult blood was positive. Further, the patient underwent a CT abdomen/pelvis with contrast, which showed a 3.7 x 3.7 x 3.2 cm mesenteric mass in the right mid-abdomen with associated desmoplastic reaction and thickening of the surrounding distal ileum, highly suspicious of carcinoid tumor. The patient’s serotonin and chromogranin levels were also reported to be elevated.

The patient was then started on vеноfer for his anemia. To locate the source of bleeding, the patient underwent esophagogastroduodenoscopy and colonoscopy. However, both tests failed to demonstrate a source of an active or recent GI bleed. The options of attempted biopsy with interventional radiology versus surgical exploration with resection of affected area and mass were discussed with the patient. Considering the patient’s symptoms and iron deficiency anemia, surgery was performed with the patient’s informed consent. The patient completed the course of vеноfer and underwent explorative laparotomy with segmental ileal resection and primary reanastomosis. Gross findings were significant for a large abnormal mass of mesentery of distal ileum with dilated and thickened overlying small bowel. There was no evidence of peritoneal implants or liver masses. Resected mass and tissue were sent for pathology. The pathology report confirmed the presence of multiple foci of well-differentiated grade 1 (G1) NET extending to the serosa and involving the mesenteric margins (Figure 1). Three out of ten lymph nodes were positive for metastatic NET with the largest lymph node measuring 1-2 cm in diameter. The tumor stage was consistent with pT4 and pN1. The early postoperative period was unremarkable, and the patient was recommended to follow up with surgery and oncology.

**FIGURE 1: Multiple foci of grade 1 (G1) well-differentiated NET extending into serosa and involving mesenteric margins**

NET: neuroendocrine tumor

**Discussion**

Small bowel, which constitutes 75% of the total length and 95% of the total surface area of the GI tract, is not a usual source for GI neoplasms due to multiple reasons. The contents of the small bowel are dilute and less irritating to the mucosa, and the transit time is rapid, which means less carcinogenic exposure. Besides, the bacterial count is low, implying that organisms may not be able to convert proto-oncogenes to oncogenes. Also, the small bowel has an abundance of immunoglobulin A containing lymphoid tissue [6]. Of all the small bowel tumors, carcinoid is of particular significance since it can present with obscure gastrointestinal bleeding (OGIB). OGIB, which represents about 5% of lower GI bleeding, is defined as active GI bleeding where the cause cannot be explained after a normal esophagogastroduodenoscopy and
colonoscopy result [7]. The source of such bleed is usually the small bowel, and the common causes vary with age, as shown in Table 1 [7].

| Age of the patient | Common cause of obscure gastrointestinal bleeding |
|--------------------|-----------------------------------------------|
| < 20 years         | Meckel diverticulum, CD                        |
| 20-60 years        | Small bowel tumors (GIST, carcinoid), CD, AVM |
| > 60 years         | AVM, small bowel tumor (GIST, carcinoid)       |

TABLE 1: Most common causes of obscure gastrointestinal bleeding

CD: Crohn’s disease; GIST: gastrointestinal stromal tumor; AVM: arteriovenous malformation

The common causes of lower GI bleeding are shown in Table 2 [8].
| Causes of lower GI bleed |
|-------------------------|
| **1. Upper GI causes**  |
| Ulcer                   |
| Neoplasm                |
| Vasculitis              |
| **2. Small bowel causes** |
| Inflammatory bowel disease |
| Neoplasm                |
| Arteriovenous malformation |
| Meckel diverticulum     |
| Mesenteric ischemia     |
| Radiation induced       |
| Infections              |
| Aortoenteric fistula    |
| **3. Colorectal causes** |
| Diverticular disease (most common) |
| Neoplasm                |
| Inflammatory bowel disease |
| Angiodysplasia          |
| Ischemic colitis        |
| Aortoenteric fistulas   |
| Post-polypectomy        |
| Infections              |
| Radiation induced       |

**TABLE 2: Common causes of lower GI bleeding**

GI: gastrointestinal

NETs of small bowel usually remain asymptomatic for a long time or can present with ill-defined symptoms [2]. The manifestation of the disease becomes more prominent when the tumor spreads to the liver (40%), or the mass results in acute complications like bowel obstruction, perforation, bleeding, or ischemia [5]. Local complications are due to the hormones...
produced by the primary tumor, which further leads to widespread mesenteric and peritoneal fibrosis [9]. Metastatic disease to the liver often presents with systemic symptoms such as diarrhea, wheezing, and flushing due to the production of vasoactive peptides like serotonin, vasoactive intestinal peptide, and histamine [10,11]. A retrospective analysis was conducted in Massachusetts on adult patients with histologically proven small bowel NETs. In that study, the majority of the patients presented with OGIB and anemia (87.5%) [12], and the leading cause of mortality was liver failure (80%) followed by bowel obstruction in 16% of the cases [9].

The initial workup of NETs consists of a CT and magnetic resonance imaging of the abdomen/pelvis [12,13]. However, despite having good sensitivity and specificity, their role in diagnosing NETs of the small bowel is often limited [13]. In the past decade, video capsule endoscopy (VCE) has emerged as an important test in diagnosing small bowel NETs [12,14]. In a retrospective analysis by Noujaim et al., the findings on VCE, including tumor location, morphology, and number, correlated with the findings obtained during surgery [12]. Furthermore, a meta-analysis by Triester et al. done on 88 patients with OGIB revealed that VCE was able to detect the source of bleeding in 67% of the patients [14]. These results are in contrast to the 8% of cases detected by small bowel radiographic studies. A study by Hakim et al. proposed that CT enterography can help identify NETs that were missed on VCE [15]. However, there is still some discrepancy between what is detected on imaging and what is observed intraoperatively [3]. NETs are usually diagnosed late, with the majority presenting with metastases to liver and lymph nodes (85.5%) [3]. Interestingly, the primary tumor often remains small. The American College of Gastroenterology guidelines in approaching a case of obscure GI bleeding is shown in Figure 2 [16,17].

![ACG guidelines for obscure GI bleeding](image)

Management of the tumors is dependent on the size and location of the lesion. Duodenal NETs that are < 1 cm can be removed through an endoscope as they are often isolated masses with no metastasis. In contrast, jejunileal tumors often require surgery and present with early
metastasis to lymph nodes and liver [2]. Ki-67 index, a histopathological marker, helps in tumor grading. A higher index signifies an aggressive tumor growth. According to the World Health Organization (WHO) classification of 2017, grade 1/grade 2 (G1/G2) tumors have a Ki-67 index of 0%-20%, and grade 3 (G3) has an index of >20% (Table 3) [3,18]. For G1 tumors, regardless of liver involvement, surgical resection of the primary tumor with radical lymph node dissection has shown survival benefit [3,9]. In contrast, for G2 tumors, data are less supportive of surgery benefit, and it is usually not recommended unless for symptomatic palliative relief [3]. For liver metastasis, management consists of surgical resection, even if the entire metastatic tumor cannot be eradicated. This is due to the fact that NETs produce vasoactive amines that precipitate liver failure (the leading cause of mortality), and tumor resection helps in preventing or at least slowing down the progression of liver failure [9]. In a cohort study conducted in Germany, the investigators observed that patients who had an R0 or R1 resection of their hepatic metastasis fared better with a five-year survival rate of 88.5% compared to 69.1% five-year survival rate in those who underwent R2 resection or no liver resection at all [3].

| WHO 2017 grading of NETs | Mitoses/10 HPF | Ki-67 index |
|--------------------------|----------------|-------------|
| Well differentiated       |                |             |
| G1                       | <2             | <3          |
| G2                       | 2 to 20        | 3 to 20     |
| G3                       | >20            | >20         |
| Poorly differentiated     |                |             |
| G3                       | >20            | >20         |

TABLE 3: WHO 2017 grading of NET

WHO: World Health Organization; NET: neuroendocrine tumor; G: grade; HPF: high-power field

Currently, immunotherapy is emerging to be a thriving option in the management of patients with GI and pancreatic NETs [19]. In the past, somatostatin analogs and interferon-alpha have shown to improve the quality of life and survival in these patients [20]. Various immunoproteins like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) are being targeted to reveal their benefits in patients with GI NETs [19]. Biotherapy is still emerging, and it is expected to unveil better benefits not only for NETs but also for many other cancers. Several clinical trials are underway, focusing on the potential benefits of biotherapy alone and in combination with chemotherapy as well (Table 4) [20].

| Study                     | Trial phase | Drug                | Mechanism of action | Conditions   |
|---------------------------|-------------|---------------------|---------------------|--------------|
| Ibrutinib in advanced     |             |                     |                     | Carcinoid tumors, |
| Study Description                                                                 | Phase | Investigational agent(s)                        | Therapeutic Effect                                                                 | Disease(s)                                                                 |
|---------------------------------------------------------------------------------|-------|------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| carcinoid and pancreatic neuroendocrine tumors                                  | Phase II | Ibrutinib                                     | Inhibits Bruton’s tyrosine kinase and hence B-cell receptor signaling              | pancreatic neuroendocrine tumors                                         |
| Fosbretabulin in subjects with pancreatic or GI neuroendocrine tumors with elevated biomarkers | Phase II | Fosbretabulin tromethamine                   | Destabilizes microtubules and targets tumor vasculature thus inhibiting angiogenesis | Neuroendocrine tumors                                                     |
| Nivolumab with ipilimumab in subjects with neuroendocrine tumors                | Phase II | Nivolumab and ipilimumab                     | Inhibits immune responses through PD-1 pathway. ipilimumab binds to CTLA-4 and blocks the normal inhibitory signal thus allowing CTLs to destroy cancer cells | Neuroendocrine tumors, carcinoid tumors                                    |
| The MetNET-2 trial (MetNET-2)                                                    | Early phase I | Lanreotide and metformin                   | Lanreotide: somatostatin analog; metformin anti-diabetic agent, recently emerged as anti-tumor agent; acts through modification of systemic metabolism or through cell pathway effects | Neuroendocrine tumors                                                     |
| Nintedanib in patients with locally advanced or metastatic neuroendocrine tumors | Phase II | Nintedanib                                     | Inhibits growth factors through inhibition of tyrosine kinase                      | Carcinoid tumor, metastatic carcinoid tumor, neuroendocrine neoplasms     |
| Everolimus and octreotide in patients with advanced carcinoid tumor (RADIANT-2) | Phase III | Octreotide vs octreotide+everolimus           | Octreotide: somatostatin analog, everolimus: inhibits mTOR                          | Carcinoid tumor, malignant carcinoid syndrome                              |
| Carfilzomib in patients with advanced neuroendocrine cancers                    | Phase II | Carfilzomib                                     | Selectively inhibits proteosomes                                                   | Neuroendocrine cancers                                                     |
| Combination chemotherapy plus interferon-alpha followed by filgrastim in patients with GI tumors | Phase II | Biological agent: filgrastim Recombinant interferon-alpha drugs: fluorouracil and hydroxyurea | Filgrastim: colony-stimulating factor; helps body make white blood cells. Recombinant interferon-alpha: therapeutic peptide, at molecular level to exert anti-viral and anti-tumor effects. Fluorouracil: anti-metabolite, anti-neoplastic agent. Hydroxyurea: anti-metabolite, slows cancer growth | Extrahepatic bile duct cancer, gastric cancer, gastrointestinal carcinoid tumor, liver cancer, pancreatic cancer, small intestine cancer |
| Telotristat etiprate-expanded treatment for patients with carcinoid syndrome symptoms (TELEPATH) | Phase III | Telotristat etiprate tablets                   | Inhibits tryptophan hydroxylase                                                   | Carcinoid syndrome                                                         |

---

2020 Vusqa et al. Cureus 12(1): e6641. DOI 10.7759/cureus.6641
Veliparib, capecitabine, and temozolomide in patients with advanced, metastatic, and recurrent neuroendocrine tumor

Capecitabine: anti-metabolite, anti-cancer drug. Temozolomide: alkylating anti-cancer drug. Veliparib: inhibits protein PARP; acts at molecular level by blocking PARP and thus allow cancer cells to respond better to other chemotherapy agents

pancreatic neuroendocrine tumor, metastatic carcinoid tumor, somatostatin-producing neuroendocrine tumors

| Phase I | Capecitabine, temozolomide, veliparib |
|---------|--------------------------------------|

Erlotinib hydrochloride and cetuximab in patients with advanced gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, or colorectal cancer

Cetuximab: EGFR (tyrosine kinase) inhibitor

Metastatic gastrointestinal carcinoid tumors, recurrent colon cancer, recurrent gastrointestinal carcinoid tumors

| Phase I | Cetuximab, erlotinib hydrochloride |
|---------|-----------------------------------|

**TABLE 4: List of various biotherapy clinical trials**

PD-1 pathway: programmed death-1 pathway; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; CTL: cytotoxic T-lymphocyte; mTOR: mammalian target of rapamycin; PARP: poly(ADP-ribose)polymerase; EGFR: epidermal growth factor receptor

**Conclusions**

Small bowel carcinoids are rare tumors that present with vague symptoms like GI bleed and anemia. A thorough investigation is required in any case of suspicious GI bleed, especially in older patients over 65 years. Management consists of surgery and various chemotherapy and immunotherapy drugs. Biotherapy is still emerging, and it is expected to unveil better benefits not only for NETs but also for many other cancers.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Bonekamp D, Raman SP, Horton KM, Fishman EK: Role of computed tomography angiography in detection and staging of small bowel carcinoid tumors. World J Radiol. 2015, 7:220-235. 10.4329/wjr.v7.i9.220
2. Kunovský L, Dastych M, Robek O, et al.: Multiple neuroendocrine tumor of small bowel: a case report and a review of literature. Vnitr Lek. 2018, 64:966-969.
3. Watzka FM, Fottner C, Miederer M, et al.: Surgical treatment of NET of small bowel: a
4. Oronsky B, Ma PC, Morgensztern D, Carter CA: Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017, 19:991-1002. 10.1007/s00268-016-3432-2
5. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS: Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2019, 249:63-71. 10.1097/SLA.0b013e31818e4641
6. Negoi I, Paun S, Hostiuc S, et al.: Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo). 2015, 13:500-505. 10.1590/S1679-45082015AO3380
7. Cotter TG, Buckley NS, Loftus CG: Approach to the patient with hematochezia. Mayo Clin Proc. 2017, 92:797-804. 10.1016/j.mayocp.2016.12.021
8. Tringali A: Endoscopic management of acute lower gastrointestinal bleeding. J Gastroenterol Hepatol Res. 2015, 4:1486-1500.
9. Farley HA, Pommier RF: Surgical treatment of small bowel neuroendocrine tumors. Hematol Oncol Clin North Am. 2016, 30:49-61. 10.1016/j.hoc.2015.09.001
10. Thomas AM, Beumer JD, Suppiah A, Devitt PG: Unusual cause of gastrointestinal bleeding: multiple small bowel carcinoid tumours. ANZ J Surg. 2017, 87:100-101. 10.1111/ans.12853
11. Strosberg J: Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol. 2012, 26:755-773. 10.1016/j.bpg.2012.12.002
12. Noujaim MG, Green J, Min M, et al.: Carcinoids and capsules: a case series highlighting the utility of capsule endoscopy in patients with small bowel carcinoids. Gastroenterology Res. 2017, 10:347-351. 10.14740/gr937w
13. ElGuindy YM, Javadi S, Menias CO, Jensen CT, Elsamaloty H, Elsayes KM: Imaging of secretory tumors of the gastrointestinal tract. Abdom Radiol. 2017, 42:1115-1131. 10.1007/s00261-016-0976-4
14. Triester SL, Leighton JA, Leontiadis GI, et al.: A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. Am J Gastroenterol. 2005, 100:2407-2418. 10.1111/j.1572-0241.2005.00274.x
15. Hakim FA, Alexander JA, Huprich JE, Grover M, Enders FT: CT-enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo Clinic Rochester. Dig Dis Sci. 2011, 56:2914-2919. 10.1007/s10620-011-1775-0
16. Fisher L, Krinsky ML, Anderson MA, et al.: The role of endoscopy in the management of obscure GI bleeding. Gastrointest Endosc. 2010, 72:471-479. 10.1016/j.gie.2010.04.032
17. Teh JW, Fowler AL, Donlon NE, et al.: Obstructive gastrointestinal bleeding resulting from small bowel neoplasia: a case series. Int J Surg Case Rep. 2019, 60:87-90. 10.1016/j.ijscr.2019.05.006
18. Choe J, Kim KW, Kim HJ, et al.: What is new in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer staging system for pancreatic neuroendocrine neoplasms? Korean J Radiol. 2019, 20:5-17. 10.3348/kjr.2018.0040
19. Oberg K: Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol. 1995, 5:110-120.
20. Papaxoinis G, Syrigos K, Saif MW: New concepts in the treatment strategy of neuroendocrine tumors: the role of biotherapy. Discov Med. 2016, 23:381-389.